• Firefly Neuroscience posted a net loss of $2 million for three months ended March 31, 2026, narrowing from $12.93 million a year earlier.
• Revenue rose to $485,000, up 1,028% year over year, while operating loss narrowed to $2.01 million from $2.07 million.
• Operating expenses increased 5% to $2.23 million, led by a 36% rise in research and development expense to $424,000.
• Cash totaled $3.13 million at March 31, 2026; company flagged substantial doubt about its ability to continue as a going concern, citing accumulated deficit of $113.62 million.
• March 2026 private placement initial closing raised $2.25 million, followed by an April 2026 additional closing that brought in $8 million in gross proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Firefly Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-016501), on May 13, 2026, and is solely responsible for the information contained therein.